The objective is to explore whether epo regulation and expression, at the age of two weeks after birth and three to six months post-term, are associated with the course of Hb levels, anemia, RBC transfusions, oxidative stress, and cerebral and…
ID
Bron
Verkorte titel
Aandoening
Preterm neonates, Anemia, Erytrhocytes/Red blood cells, Erythropoietin
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The primary outcome measure will be epo regulation and expression at various ages: baseline epo concentration in umbilical cord blood, epo concentration in blood at the age of two weeks after birth, the degree of DNA methylation in intestinal cells isolated from feces at the age of two weeks after birth, and the degree of DNA methylation in intestinal cells isolated from feces at the age of three to six months post-term. Additionally, if one of the included infants developed NEC and needs surgery, then a small part of the removed intestine will be analysed in laboratory for intestinal epo gene expression, comparing it with an healthy part which is already available in the laboratory. <br>
Furthermore, we will use Hb levels assessed during standard care and collect information (number and volume) regarding RBC transfusions during the first four weeks of life. Cerebral and intestinal oxygen saturation during the first four weeks after birth and urinary isoprostane concentrations, as biomarker for oxidative stress, will also be determined.
Achtergrond van het onderzoek
Neonatal anemia is common in preterm infants. Anemia may lead to hypoxia, possibly resulting in cell damage. A red blood cell (RBC) transfusion is an intervention aiming to rapidly improve oxygen transport to vital organs, such as the brain and the gut.
Anemia and RBC transfusions result in low and high organ oxygenation respectively. Both might be harmful, and especially high variation in oxygenation may lead to damage in vulnerable organs, such as the brain and the gut. As erythropoiesis is partly upregulated by hypoxia, there might be an association between these oxygenation values and the expression of erythropoietin (epo), which is the essential growth factor for the production of erythrocytes. Anemia leads to decreased oxygen transport and decreased organ oxygenation, whereas RBC transfusion increases oxygenation. It is unknown whether anemia and/or RBC transfusion are related to the expression of epo in gut cells through these various levels of oxygenation. We will therefore explore whether epo regulation and expression in intestinal cells may be associated with the course of hemoglobin (Hb) levels. Furthermore, we will explore if epo regulation and expression may also be associated with anemia, RBC transfusions, oxidative stress, and organ oxygenation in the neonatal period. Secondary, we will evaluate the clinical consequences and the neurological outcome of the variable oxygenation levels.
Doel van het onderzoek
The objective is to explore whether epo regulation and expression, at the age of two weeks after birth and three to six months post-term, are associated with the course of Hb levels, anemia, RBC transfusions, oxidative stress, and cerebral and intestinal oxygenation in preterm infants during the early neonatal period.
Onderzoeksopzet
The duration of the study will be from informed consent, followed by inclusion (after admission to the NICU) until three to six months post-term. The study period at the NICU will be for a maximum of four weeks. During the study period at the NICU the patients will undergo several non-invasive measurements.
Onderzoeksproduct en/of interventie
None
Publiek
E.M.W. Kooi
kinderarts-neonatoloog, afdeling neonatologie
Beatrix Kinderziekenhuis, UMC Groningen
Huispostcode: CA 51
Hanzeplein 1
Postbus 30001
Groningen 9700 RB
The Netherlands
050-3614215
e.kooi@umcg.nl
Wetenschappelijk
E.M.W. Kooi
kinderarts-neonatoloog, afdeling neonatologie
Beatrix Kinderziekenhuis, UMC Groningen
Huispostcode: CA 51
Hanzeplein 1
Postbus 30001
Groningen 9700 RB
The Netherlands
050-3614215
e.kooi@umcg.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- A gestational age < 32 weeks
- Before 7 days of age
- Written informed consent by legal representative(s)
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Chromosomal abnormality (e.g. trisomy 13, 18, 21)
- Perinatal asphyxia resulting in Apgar score (AS) < 5 at five minutes postpartum
- Major congenital malformations that increase the risk of death or adverse neurodevelopmental outcome (congenital cerebral malformations, congenital heart diseases excluding patent ductus arteriosus)
- Intraventricular and periventricular hemorrhage > grade 2 according to Papile, prior to inclusion
- Diagnosis of NEC prior to inclusion
- Alloimmune hemolytic disease, sickle-cell disease or thalassemia
- Any received RBC transfusions prior to inclusion
- Inability to understand Dutch by the parents
- Parents expressing strong philosophical or religious objections to transfusion
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL6447 |
NTR-old | NTR6625 |
CCMO | NL62348.042.17 |
OMON | NL-OMON48979 |